A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2) (NCT07359846)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma
🩺 Plain-English Summary (8th-Grade Level)
The objective of this study is to assess the potential for GB-0895 treatment to improve the health of adolescents and adults with severe asthma that is uncontrolled by inhaled corticosteroids (ICS) and conventional asthma controllers. The study details include: Study treatment: randomized to receive either GB-0895 or placebo administered every 6 months over 52 weeks. Visit frequency: every 1-2 months after the first month.
Who can join: Review the eligibility criteria below.
Location: Research Site 13 — Bakersfield, California
Age range: 12 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (68 Sites)
Showing the first 25 of 68 sites.
- Research Site 13 — Bakersfield, California
- Research Site 12 — Inglewood, California
- Research Site 65 — Lancaster, California
- Research Site 10 — West Covina, California
- Research Site 06 — Miami, Florida
- Research Site 03 — Miami, Florida
- Research 09 — Orlando, Florida
- Research Site 01 — Tamarac, Florida
- Research Site 04 — Tampa, Florida
- Research Site 05 — Tampa, Florida
- Research Site 20 — Fall River, Massachusetts
- Research Site 02 — Ypsilanti, Michigan
- Research Site 69 — New York, New York
- Research Site 11 — Dayton, Ohio
- Research Site 21 — Oklahoma City, Oklahoma
- Research Site 16 — Rock Hill, South Carolina
- Research Site 17 — San Antonio, Texas
- Research Site 07 — Sugar Land, Texas
- Research Site 08 — Williamsburg, Virginia
- Research Site 31 — Ciudad Autónoma de Buenos Aires, Buenos Aires
- Research Site 33 — Ciudad Autónoma de Buenos Aires, Buenos Aires
- Research Site 67 — Buenos Aires, Buenos Aires F.D.
- Research site 39 — Southport, Queensland
- Research Site 22 — Mechelen, Vlaams Brabant
- Research Site 45 — Erpent,
📞 Contact the Study Coordinator
Phone: (888) 469-0033
Email: solairiastudy@generatebiomedicines.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Severe Asthma
- A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR) — Bakersfield, California
- Using NLP and Neural Networks to Autonomously Identify Severe Asthma and Determine Study Eligibility in a Large Healthcare System — San Diego, California
- Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. — Palmdale, California
- Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA) — Edmonton, Alberta
- International Severe Asthma Registry: Canadian Cohort — Edmonton, Alberta
Explore by condition: All Severe Asthma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.